ArticleScientific reports2025
Sustainable approach for synthesis of new coumarin-linked Schiff bases in DABCO-based ionic liquid and their identification as aldose reductase inhibitors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aldehyde reductase (ALR1) is the enzyme that speeds up the reduction of many types of aldehydes into sorbitol and D-glucose. The essential enzyme of the polyol pathway, aldose reductase (ALR2), is responsible for the development of chronic complications associated with diabetes when activated under hyperglycemic conditions. Since it is a crucial mediator for the oxidative and inflammatory signaling pathways, ALR is thought to be a target for various diseases. Many medicines are available for the treatment of ALR-associated issues but due to their long term side-effects they are not effectively used. Coumarin is a naturally occurring compound, and its derivatives are widely used in the treatment of many ailments. Therefore, in the pursuit to find potential alternate candidates as drug leads, we have prepared new coumarin-based Schiff base analogues using DABCO-C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.